F. Jänicke

17.2k total citations · 2 hit papers
183 papers, 11.3k citations indexed

About

F. Jänicke is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, F. Jänicke has authored 183 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Cancer Research, 98 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in F. Jänicke's work include Protease and Inhibitor Mechanisms (48 papers), Breast Cancer Treatment Studies (37 papers) and HER2/EGFR in Cancer Research (35 papers). F. Jänicke is often cited by papers focused on Protease and Inhibitor Mechanisms (48 papers), Breast Cancer Treatment Studies (37 papers) and HER2/EGFR in Cancer Research (35 papers). F. Jänicke collaborates with scholars based in Germany, Switzerland and United States. F. Jänicke's co-authors include Manfred Schmitt, H. Graeff, Nadia Harbeck, Christoph Thomssen, Klaus Pantel, Volkmar Müller, Norbert Avril, L. Pache, J. Dose and Sabine Riethdorf and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Genetics.

In The Last Decade

F. Jänicke

177 papers receiving 11.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

2007 1.1k citations Sabine Riethdorf, Herbert A. Fritsche et al. profile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 790 citations Matthew J. Ellis, Andrew Coop et al. profile →

Peers

Countries citing papers authored by F. Jänicke

Since Specialization

Citations

This map shows the geographic impact of F. Jänicke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Jänicke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Jänicke more than expected).

Fields of papers citing papers by F. Jänicke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Jänicke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Jänicke. The network helps show where F. Jänicke may publish in the future.

Co-authorship network of co-authors of F. Jänicke

This figure shows the co-authorship network connecting the top 25 collaborators of F. Jänicke. A scholar is included among the top collaborators of F. Jänicke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Jänicke. F. Jänicke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group 2023 ·Cancers ·Christoph Thomssen, Martina Vetter, Eva Johanna Kantelhardt, Christoph Meisner, Marcus Schmidt, Pierre Martin, Florian Clatot, Doris Augustin, Volker Hanf, (unknown), Wolfgang Meinerz, G. M. Hoffmann, W. Wiest, Fred C.G.J. Sweep, Manfred Schmitt, F. Jänicke, Sibylle Loibl, Gϋnter von Minckwitz, Nadia Harbeck	0
2	Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial 2016 ·Annals of Oncology ·Oleg Gluz, C Liedtke, Jens Huober, (unknown), Ronald Kates, Hans Kreipe, Arndt Hartmann, Enrico Pelz, Ramona Erber, Svjetlana Mohrmann, Volker Möbus, Doris Augustin, G. M. Hoffmann, Christoph Thomssen, F. Jänicke, Marion Kiechle, D. Wallwiener, W. Kühn, Ulrike Nitz, Nadia Harbeck	10
3	Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry 2014 ·BMC Cancer ·Isabell Witzel, Volkmar Müller, Wolfgang Abenhardt, Manfred Kaufmann, Winfried Schoenegg, (unknown), F. Jänicke	31
4	Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers 2013 ·Journal of Cancer Research and Clinical Oncology ·Isabell Witzel, Monika Graeser, Thomas Karn, M Schmidt, Ralph M. Wirtz, (unknown), (unknown), F. Jänicke, Karin Milde‐Langosch, Volkmar Müller	30
5	Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer 2011 ·Onkologie ·Isabell Witzel, Eva Johanna Kantelhardt, Karin Milde‐Langosch, Maike Ihnen, (unknown), Nadia Harbeck, F. Jänicke, Volkmar Müller	19
6	Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases. 2010 ·SHILAP Revista de lepidopterología ·Maike Ihnen, (unknown), (unknown), Karin Milde‐Langosch, (unknown), Sylvia Höller, Volkmar Müller, Isabell Witzel, F. Jänicke, (unknown)	15
7	Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. 2009 ·PubMed ·(unknown), Thomas Löning, Volkmar Müller, Christine Schröder, F. Jänicke, Karin Milde‐Langosch	18
8	Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer - A multi-center validation study of the CellSearch™ system. 2006 ·Cancer Research ·Sabine Riethdorf, Volkmar Müller, Cornelia Coith, (unknown), F. Jänicke, Herbert A. Fritsche, Summer Jackson, (unknown), Klaus Pantel	13
9	Clinical Utility of Determination of HER-2/neu and EGFR Fragments in Serum of Patients with Metastatic Breast Cancer 2006 ·The International Journal of Biological Markers ·Isabell Witzel, Christoph Thomssen, (unknown), Waldemar Wilczak, Michaël Bubenheim, Klaus Pantel, R. Neumann, F. Jänicke, (unknown)	17
10	Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. 2003 ·PubMed ·Matthew J. Ellis, Andrew Coop, Baljit Singh, Tao Yu, Antonio Llombart‐Cussac, F. Jänicke, L. Mauriac, Erhard Quebe‐Fehling, Hilary A. Chaudri‐Ross, Dean B. Evans, William R. Miller	167
11	Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy 2003 ·Annals of Oncology ·Peter Reichardt, Gϋnter von Minckwitz, Peter Thuss‐Patience, W. Jonat, H Kölbl, F. Jänicke, D G Kieback, W. Kühn, A. E. Schindler, Svjetlana Mohrmann, M. Kaufmann, Hans‐Joachim Lück	202
12	Influence of Preharvest Tumor Cell Contamination in Bone Marrow or Blood Does Not Predict Resultant Tumor Cell Contamination of Granulocyte Colony-Stimulating Factor Mobilized Stem Cells 2001 ·Journal of Hematotherapy & Stem Cell Research ·William Krüger, Nicolaus Kröger, Florian Tögel, Anita Badbaran, Helmut Renges, Friederike Gieseking, K. Gutensohn, F. Jänicke, Axel R. Zander	5
13	Disseminated Breast Cancer Cells Prior to and After High-Dose Therapy 2001 ·Journal of Hematotherapy & Stem Cell Research ·William Krüger, Nicolaus Kröger, Florian Tögel, Helmut Renges, Anita Badbaran, René Hornung, Roman Jung, K. Gutensohn, Friederike Gieseking, F. Jänicke, Axel R. Zander	13
14	Urokinase-like Plasminogen Activator Receptor Expression on Disseminated Breast Cancer Cells 2001 ·Journal of Hematotherapy & Stem Cell Research ·Florian Tögel, (unknown), Anita Badbaran, Nicolaus Kröger, Helmut Renges, Friederike Gieseking, F. Jänicke, Axel R. Zander, William Krüger	15
15	The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV 1998 ·International Journal of Gynecological Cancer ·W. Kühn, G. Florack, J. D. Roder, Barbara Schmalfeldt, L. Pache, George Rust, K. Ulm, K Späthe, F. Jänicke, J. R. Siewert, H. Graeff	45
16	Positron Emission Tomography for Diagnosis of Breast Tumors 1997 ·Oncology Research and Treatment ·J. Dose, Norbert Avril, H. Graeff, F. Jänicke	2
17	Clinical Relevance of Detection of Tumor Cells in the Bone Marrow of Primary Breast Cancer Patients: A Review 1997 ·Oncology Research and Treatment ·Nadia Harbeck, (unknown), F. Jänicke	4
18	Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. 1995 ·PubMed ·Barbara Schmalfeldt, W. Kühn, Ute Reuning, L. Pache, P. Dettmar, Manfred Schmitt, F. Jänicke, Heinz Höfler, H. Graeff	85
19	Durchflußzytometrische DNA-Analyse von reinen Zellkernen aus formalin-fixierten Paraffinschnitten beim primären Mammakarzinom: Korrelation mit anderen Prognosefaktoren 1991 ·Gyn�kologisch-geburtshilfliche Rundschau ·Nadia Harbeck, Nobuhiko Moniwa, Evan L. Busch, (unknown), F. Jänicke, (unknown), Heinz Höfler, H. Graeff	0
20	Klinische und prognostische Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie* 1991 ·Geburtshilfe und Frauenheilkunde ·H. Graeff, F. Jänicke, Markus Schmitt	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact